haloperidol has been researched along with Weight Gain in 83 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
Weight Gain: Increase in BODY WEIGHT over existing weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This Japanese, multicenter, randomized, double-blind trial, evaluating the efficacy and safety of blonanserin compared with haloperidol in patients with schizophrenia, was previously published by Murasaki in the Japanese language." | 9.30 | Blonanserin versus haloperidol in Japanese patients with schizophrenia: A phase 3, 8-week, double-blind, multicenter, randomized controlled study. ( Harvey, PD; Murasaki, M; Nakamura, H, 2019) |
| "In adults with schizophrenia or schizoaffective disorder, use of paliperidone palmitate vs haloperidol decanoate did not result in a statistically significant difference in efficacy failure, but was associated with more weight gain and greater increases in serum prolactin, whereas haloperidol decanoate was associated with more akathisia." | 9.19 | Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. ( Buckley, PF; Byerly, M; Dominik, R; Hamer, RM; Lamberti, JS; McEvoy, JP; Ray, N; Rosenheck, RA; Stroup, TS; Swartz, MS; Wilkins, TM, 2014) |
| " The goal of this study was to assess the effects of clozapine and olanzapine in comparison to the first-generation agent haloperidol on these metabolic parameters in aggressive patients with schizophrenia." | 9.14 | Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol. ( Citrome, L; Czobor, P; Krakowski, M, 2009) |
| "Newly diagnosed patients with first-episode schizophrenia treated with antipsychotic medication-olanzapine, risperidone, or haloperidol-and matched healthy controls were followed for 6 weeks." | 9.13 | Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. ( Akhtar, S; Ameen, S; Saddichha, S, 2008) |
| "To quantify the weight gain induced by first (haloperidol) and second generation antipsychotics (olanzapine and risperidone) in a cohort of drug-naïve subjects after 1 year of treatment." | 9.13 | Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naïve population. ( Alvarez-Jimenez, M; Amado, JA; Crespo-Facorro, B; Garcia-Unzueta, MT; Martinez-Garcia, O; Pelayo-Teran, JM; Perez-Iglesias, R; Ramirez-Bonilla, ML; Vazquez-Barquero, JL, 2008) |
| "The aim of the study was to investigate safety, efficacy and tolerability of risperidone in comparison with haloperidol in the long-term treatment of autistic disorder." | 9.13 | Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder. An open label maintenance study. ( Baykara, A; Baykara, B; Dirik, E; Emiroglu, FN; Gencer, O; Miral, S, 2008) |
| "To evaluate the extent, time course and predictors of weight gain and its effect on study retention among people with first-episode psychosis treated with olanzapine or haloperidol." | 9.11 | Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. ( Green, AI; Gu, H; Gur, RE; Kahn, RS; Lieberman, JA; McEvoy, JP; Perkins, DO; Sharma, T; Strakowski, SM; Tohen, MF; Tollefson, GD; Zipursky, RB, 2005) |
| "The authors studied weight gain mechanisms and energy balance in patients treated with olanzapine." | 9.10 | Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. ( Apter, A; Constantini, N; Falk, B; Frishman, S; Gothelf, D; Kairi, M; Phillip, M; Poraz, I; Singer, P; Weizman, A; Zalsman, G; Zigel, L, 2002) |
| "Weight change and the weight-related health factors of nonfasting serum glucose, serum cholesterol, and diastolic blood pressure levels were analyzed in patients with DSM-III-R schizophrenia and related disorders who received treatment with olanzapine for up to 3 years, and comparisons were made to patients treated with haloperidol." | 9.09 | Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. ( Basson, BR; Gilmore, JA; Kinon, BJ; Tollefson, GD, 2001) |
| "Clinical factors predicting weight change in patients with schizophrenia and related disorders during acute treatment with the antipsychotic drugs olanzapine, risperidone, and haloperidol were sought through retrospective analyses." | 9.09 | Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. ( Basson, BR; Gilmore, JA; Kinon, BJ; Szymanski, KA; Taylor, CC; Tollefson, GD, 2001) |
| "Patients were investigated to gain more insight into the incidence and time course of clozapine induced weight gain (n = 81) and to compare weight gain in patients treated with clozapine (n = 31) with that of patients treated with standard antipsychotics (haloperidol, n = 11)." | 9.08 | Weight gain induced by clozapine. ( Fleischhacker, WW; Hummer, M; Kemmler, G; Kurz, M; Kurzthaler, I; Oberbauer, H, 1995) |
| "Between 40% and 70% of people with treatment-resistant schizophrenia do not respond to clozapine, despite adequate blood levels." | 8.95 | Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. ( Barber, S; Cipriani, A; Corsi, M; Olotu, U, 2017) |
| "To review the effects in clinical response of haloperidol and low-potency antipsychotics for people with schizophrenia." | 8.90 | Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia. ( Engel, RR; Huhn, M; Kissling, W; Leucht, S; Tardy, M, 2014) |
| "Haloperidol or clozapine was orally fed to male and female Sprague Dawley rats for 12 weeks, and body weight gain, food and water intake were measured." | 7.79 | The sex-dependent impact of chronic clozapine and haloperidol treatment on characteristics of the metabolic syndrome in a rat model. ( Bouvier, ML; Gaebel, W; Henning, U; Schmitt, A; Schneider-Axmann, T; von Wilmsdorff, M, 2013) |
| " The present study was undertaken to investigate the role of GABA(A) receptors within the framework of nucleus accumbens shell (AcbSh) in haloperidol-induced hyperphagia and body weight gain in sated rats." | 7.75 | GABAA receptors in nucleus accumbens shell mediate the hyperphagia and weight gain following haloperidol treatment in rats. ( Kokare, DM; Meena, H; Nakhate, KT; Subhedar, NK, 2009) |
| "We have investigated the contribution of effects at these receptors to olanzapine-induced weight gain occurring over 5 days following daily intraperitoneal drug injections in groups of eight female rats." | 7.75 | Olanzapine-induced weight gain in the rat: role of 5-HT2C and histamine H1 receptors. ( Glazebrook, J; Grayson, B; Kirk, SL; Neill, JC; Reynolds, GP, 2009) |
| "Our results support the previously reported positive impact of atypical antipsychotics, particularly olanzapine, in patients with schizophrenia." | 7.72 | Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. ( Bitter, I; Boland, J; Dossenbach, M; el Mahfoud Kessaci, M; Erol, A; Hodge, A; O'Halloran, RA; Shaheen, MO; Sunbol, MM, 2004) |
| "Outpatients diagnosed of schizophrenia according to DSM-IV criteria and receiving a single antipsychotic (risperidone, olanzapine, quetiapine or haloperidol) for at least 4 weeks were consecutively recruited." | 7.72 | Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. ( Bobes, J; Fernández, I; Garcia-Garcia, M; García-Portilla, MP; Hernández, G; Rejas, J; Rico-Villademoros, F, 2003) |
| "To evaluate weight gain associated with olanzapine, risperidone, and haloperidol treatment and its clinical risk factors in adolescent patients." | 7.71 | Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. ( Apter, A; Brand-Gothelf, A; Gal, G; Gothelf, D; Kikinzon, L; Phillip, M; Ratzoni, G; Reidman, J; Weizman, R, 2002) |
| "Weight gain induced by clozapine or olanzapine appears to be associated with an increase in leptin level that cannot be attributed to dietary changes upon hospitalization." | 7.70 | Body weight and leptin plasma levels during treatment with antipsychotic drugs. ( Haack, M; Hinze-Selch, D; Kraus, T; Kühn, M; Pollmächer, T; Schuld, A; Uhr, M, 1999) |
| "Treatment with Bifeprunox was found to significantly reduce all of the measured parameters except white fat mass compared to the control group." | 5.40 | Different effects of bifeprunox, aripiprazole, and haloperidol on body weight gain, food and water intake, and locomotor activity in rats. ( De Santis, M; Deng, C; Huang, XF; Lian, J; Pan, B, 2014) |
| "Haloperidol patients were more often single and institutionalised, less educated, had more residual schizophrenia, were longer hospitalised in the previous year, took more corrective and psychotropic drugs and had more extrapyramidal symptoms (EPS) and gynaecomastia (all significantly)." | 5.35 | Belgian Schizophrenia Outcome Survey - results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol. ( Albert, A; De Graeve, D; Gillain, B; Peuskens, J; Van Vleymen, B, 2009) |
| "This Japanese, multicenter, randomized, double-blind trial, evaluating the efficacy and safety of blonanserin compared with haloperidol in patients with schizophrenia, was previously published by Murasaki in the Japanese language." | 5.30 | Blonanserin versus haloperidol in Japanese patients with schizophrenia: A phase 3, 8-week, double-blind, multicenter, randomized controlled study. ( Harvey, PD; Murasaki, M; Nakamura, H, 2019) |
| " In patients with acute exacerbation, amisulpride, aripiprazole, brexpiprazole, cariprazine, haloperidol, lumateperone, and lurasidone produced mild weight gain in comparison to placebo (mean difference at any dose≤1 kg), while more significant weight gain was observed by all other drugs." | 5.22 | Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized Controlled Trials. ( Davis, JM; Hamza, T; Leucht, S; Salanti, G; Schneider-Thoma, J; Siafis, S; Wu, H, 2022) |
| "In adults with schizophrenia or schizoaffective disorder, use of paliperidone palmitate vs haloperidol decanoate did not result in a statistically significant difference in efficacy failure, but was associated with more weight gain and greater increases in serum prolactin, whereas haloperidol decanoate was associated with more akathisia." | 5.19 | Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. ( Buckley, PF; Byerly, M; Dominik, R; Hamer, RM; Lamberti, JS; McEvoy, JP; Ray, N; Rosenheck, RA; Stroup, TS; Swartz, MS; Wilkins, TM, 2014) |
| "From December 2004 through March 2008, adult outpatients with a Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition diagnosis of schizophrenia or schizoaffective disorder who were taking haloperidol decanoate (n = 40) or fluphenazine decanoate (n = 22) were randomly assigned to stay on current long-acting injectable medication or switch to risperidone microspheres and followed for 6 months under study protocol and an additional 6 months naturalistic follow-up." | 5.16 | Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial. ( Covell, NH; Essock, SM; Jackson, CT; McEvoy, JP; Rojas, IA; Schooler, NR; Stroup, TS, 2012) |
| " The goal of this study was to assess the effects of clozapine and olanzapine in comparison to the first-generation agent haloperidol on these metabolic parameters in aggressive patients with schizophrenia." | 5.14 | Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol. ( Citrome, L; Czobor, P; Krakowski, M, 2009) |
| "To quantify the weight gain induced by first (haloperidol) and second generation antipsychotics (olanzapine and risperidone) in a cohort of drug-naïve subjects after 1 year of treatment." | 5.13 | Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naïve population. ( Alvarez-Jimenez, M; Amado, JA; Crespo-Facorro, B; Garcia-Unzueta, MT; Martinez-Garcia, O; Pelayo-Teran, JM; Perez-Iglesias, R; Ramirez-Bonilla, ML; Vazquez-Barquero, JL, 2008) |
| "Newly diagnosed patients with first-episode schizophrenia treated with antipsychotic medication-olanzapine, risperidone, or haloperidol-and matched healthy controls were followed for 6 weeks." | 5.13 | Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. ( Akhtar, S; Ameen, S; Saddichha, S, 2008) |
| "The aim of the study was to investigate safety, efficacy and tolerability of risperidone in comparison with haloperidol in the long-term treatment of autistic disorder." | 5.13 | Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder. An open label maintenance study. ( Baykara, A; Baykara, B; Dirik, E; Emiroglu, FN; Gencer, O; Miral, S, 2008) |
| " This study assessed the impact of acute treatment-emergent weight gain on clinical and functional outcomes of patients with schizophrenia by patient gender and antipsychotic treatment (olanzapine or haloperidol)." | 5.11 | Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia. ( Ascher-Svanum, H; Kinon, BJ; Stensland, M; Zhao, Z, 2005) |
| "To evaluate the extent, time course and predictors of weight gain and its effect on study retention among people with first-episode psychosis treated with olanzapine or haloperidol." | 5.11 | Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. ( Green, AI; Gu, H; Gur, RE; Kahn, RS; Lieberman, JA; McEvoy, JP; Perkins, DO; Sharma, T; Strakowski, SM; Tohen, MF; Tollefson, GD; Zipursky, RB, 2005) |
| " Fifty subjects met the DSM-III-R criteria for schizophrenia or schizoaffective disorder, participated in a 10-week, double-blind comparison of haloperidol and clozapine and a 1-year, open-label clozapine trial, and had available serum glucose and lipid levels." | 5.10 | Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic antagonist treatment. ( Ball, P; Baymiller, SP; Buchanan, RW; McMahon, RP, 2003) |
| " The authors' goal was to assess the effects of clozapine, olanzapine, risperidone, and haloperidol on glucose and cholesterol levels in hospitalized patients with schizophrenia or schizoaffective disorder during a randomized double-blind 14-week trial." | 5.10 | Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2003) |
| "The authors studied weight gain mechanisms and energy balance in patients treated with olanzapine." | 5.10 | Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. ( Apter, A; Constantini, N; Falk, B; Frishman, S; Gothelf, D; Kairi, M; Phillip, M; Poraz, I; Singer, P; Weizman, A; Zalsman, G; Zigel, L, 2002) |
| "Clinical factors predicting weight change in patients with schizophrenia and related disorders during acute treatment with the antipsychotic drugs olanzapine, risperidone, and haloperidol were sought through retrospective analyses." | 5.09 | Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. ( Basson, BR; Gilmore, JA; Kinon, BJ; Szymanski, KA; Taylor, CC; Tollefson, GD, 2001) |
| "We performed a retrospective analysis of 122 clinical records of 92 male patients with DSM-III-R schizophrenia to examine the relative weight gain liabilities of clozapine, risperidone, olanzapine, and sertindole compared with haloperidol." | 5.09 | Novel antipsychotics: comparison of weight gain liabilities. ( Berisford, MA; Goldstein, D; Kysar, L; Marder, SR; Mintz, J; Pashdag, J; Wirshing, DA; Wirshing, WC, 1999) |
| "Data from a 15-site double-blind, randomized clinical trial (N = 423) were used to compare patients with DSM-III-R schizophrenia assigned to clozapine or haloperidol in terms of duration of participation while taking the randomly assigned study drug (continuation) and the proportion of prescribed pills that were taken (compliance)." | 5.09 | Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. ( Chang, S; Charney, D; Choe, Y; Cramer, J; Henderson, W; Rosenheck, R; Thomas, J; Xu, W, 2000) |
| "Weight change and the weight-related health factors of nonfasting serum glucose, serum cholesterol, and diastolic blood pressure levels were analyzed in patients with DSM-III-R schizophrenia and related disorders who received treatment with olanzapine for up to 3 years, and comparisons were made to patients treated with haloperidol." | 5.09 | Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. ( Basson, BR; Gilmore, JA; Kinon, BJ; Tollefson, GD, 2001) |
| "Patients were investigated to gain more insight into the incidence and time course of clozapine induced weight gain (n = 81) and to compare weight gain in patients treated with clozapine (n = 31) with that of patients treated with standard antipsychotics (haloperidol, n = 11)." | 5.08 | Weight gain induced by clozapine. ( Fleischhacker, WW; Hummer, M; Kemmler, G; Kurz, M; Kurzthaler, I; Oberbauer, H, 1995) |
| "The weight and symptoms of 39 outpatients with schizophrenia who were randomly assigned to double-blind treatment with either clozapine or haloperidol were assessed." | 5.08 | Differential effect of clozapine on weight: a controlled study. ( Breier, A; Buchanan, RW; Bustillo, JR; Irish, D, 1996) |
| "Between 40% and 70% of people with treatment-resistant schizophrenia do not respond to clozapine, despite adequate blood levels." | 4.95 | Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. ( Barber, S; Cipriani, A; Corsi, M; Olotu, U, 2017) |
| "To review the effects in clinical response of haloperidol and low-potency antipsychotics for people with schizophrenia." | 4.90 | Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia. ( Engel, RR; Huhn, M; Kissling, W; Leucht, S; Tardy, M, 2014) |
| " When the risk of adverse effects is analyzed, olanzapine and clozapine are afflicted with the highest risk of inducing weight gain and haloperidol with extrapyramidal symptoms." | 4.87 | A review and Bayesian meta-analysis of clinical efficacy and adverse effects of 4 atypical neuroleptic drugs compared with haloperidol and placebo. ( Aursnes, I; Gaasemyr, J; Klemp, M; Natvig, B; Skomedal, T; Tvete, IF, 2011) |
| " This reveals that the atypical antipsychotics are most likely to induce weight gain, in particular clozapine and olanzapine." | 4.82 | [Psychotropics and weight gain]. ( Bryois, Ch; Sahli, Ch, 2004) |
| "Clinical safety data for treatment of acute schizophrenia with olanzapine, a new atypical antipsychotic agent, are summarized." | 4.79 | Safety of olanzapine. ( Beasley, CM; Tollefson, GD; Tran, PV, 1997) |
| " Further, fewer preclinical adverse events were noted with 17m compared with risperidone in assays that measured prolactin secretion and weight gain." | 3.79 | Synthesis and biological investigation of coumarin piperazine (piperidine) derivatives as potential multireceptor atypical antipsychotics. ( Chen, Y; Liu, BF; Liu, S; Liu, X; Qiu, Y; Wang, S; Xu, X; Yu, M; Zhang, G; Zhang, T; Zhao, S, 2013) |
| "Haloperidol or clozapine was orally fed to male and female Sprague Dawley rats for 12 weeks, and body weight gain, food and water intake were measured." | 3.79 | The sex-dependent impact of chronic clozapine and haloperidol treatment on characteristics of the metabolic syndrome in a rat model. ( Bouvier, ML; Gaebel, W; Henning, U; Schmitt, A; Schneider-Axmann, T; von Wilmsdorff, M, 2013) |
| "Rats medicated with haloperidol and ziprasidone showed a significantly decreased percentage weight gain and food consumption." | 3.76 | The impact of antipsychotic drugs on food intake and body weight and on leptin levels in blood and hypothalamic ob-r leptin receptor expression in wistar rats. ( Bouvier, ML; Gaebel, W; Henning, U; Schmitt, A; von Wilmsdorff, M, 2010) |
| "The antipsychotic drug, olanzapine, often induces weight gain and glucose metabolism disturbances, which may result from feeding pattern abnormalities." | 3.75 | Early perturbation in feeding behaviour and energy homeostasy in olanzapine-treated rats. ( de Beaurepaire, R; Even, PC; Fromentin, G; Hermier, D; Huneau, JF; Tomé, D; Victoriano, M, 2009) |
| "We have investigated the contribution of effects at these receptors to olanzapine-induced weight gain occurring over 5 days following daily intraperitoneal drug injections in groups of eight female rats." | 3.75 | Olanzapine-induced weight gain in the rat: role of 5-HT2C and histamine H1 receptors. ( Glazebrook, J; Grayson, B; Kirk, SL; Neill, JC; Reynolds, GP, 2009) |
| " The influence of a classical antipsychotic (haloperidol) was compared to that of two atypical antipsychotics, one known to favor weight gain (olanzapine), the other not (ziprasidone)." | 3.74 | Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment. ( Carpéné, C; Daviaud, D; de Beaurepaire, R; Even, PC; Minet-Ringuet, J; Prévot, D; Quignard-Boulange, A; Tomé, D; Valet, P; Visentin, V, 2007) |
| "A 26-year-old woman with schizophrenia gained 7 kg over the course of 1 year after starting treatment with olanzapine." | 3.73 | Body weight gain induced by a newer antipsychotic agent reversed as negative symptoms improved. ( Koga, M; Nakayama, K, 2005) |
| " Data from a randomized, double-blind trial comparing treatment of schizophrenia with placebo and olanzapine were used to correlate weight change and change in psychopathology." | 3.73 | Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic. ( Ascher-Svanum, H; Kinon, BJ; Stensland, MD; Tollefson, GD, 2005) |
| "5 and 2 mg of olanzapine, but not lower doses, increase body weight and subcutaneous fat deposition." | 3.73 | A model for antipsychotic-induced obesity in the male rat. ( de Beaurepaire, R; Even, PC; Lacroix, M; Minet-Ringuet, J; Tomé, D, 2006) |
| " To investigate the possible mechanisms of antipsychotic-induced metabolic effects, we studied the impact of chronic administration of a typical antipsychotic drug (haloperidol) and an atypical antipsychotic (risperidone) to male rats on food intake, body weight, adiposity, and the circulating concentrations of hormones and metabolites that can influence energy homeostasis." | 3.73 | Distinct endocrine effects of chronic haloperidol or risperidone administration in male rats. ( Dedova, I; Duffy, L; Herzog, H; Karl, T; Lee, NJ; Lin, EJ; Matsumoto, I; O'brien, E; Sainsbury, A; Slack, K, 2006) |
| "Several clinical reports have demonstrated that most antipsychotics of the new generation, but not the typical antipsychotic haloperidol, induce weight gain in schizophrenic patients." | 3.72 | Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human. ( Kreilgaard, M; Mow, T; Pouzet, B; Velschow, S, 2003) |
| "Our results support the previously reported positive impact of atypical antipsychotics, particularly olanzapine, in patients with schizophrenia." | 3.72 | Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. ( Bitter, I; Boland, J; Dossenbach, M; el Mahfoud Kessaci, M; Erol, A; Hodge, A; O'Halloran, RA; Shaheen, MO; Sunbol, MM, 2004) |
| "Outpatients diagnosed of schizophrenia according to DSM-IV criteria and receiving a single antipsychotic (risperidone, olanzapine, quetiapine or haloperidol) for at least 4 weeks were consecutively recruited." | 3.72 | Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. ( Bobes, J; Fernández, I; Garcia-Garcia, M; García-Portilla, MP; Hernández, G; Rejas, J; Rico-Villademoros, F, 2003) |
| " However, accumulating evidence suggests that these agents, particularly clozapine and olanzapine, have serious side effects of their own, including weight gain and elevated glucose and triglyceride levels." | 3.71 | The effects of novel antipsychotics on glucose and lipid levels. ( Ballon, JS; Boyd, JA; Marder, SR; Meng, LR; Wirshing, DA; Wirshing, WC, 2002) |
| "To evaluate weight gain associated with olanzapine, risperidone, and haloperidol treatment and its clinical risk factors in adolescent patients." | 3.71 | Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. ( Apter, A; Brand-Gothelf, A; Gal, G; Gothelf, D; Kikinzon, L; Phillip, M; Ratzoni, G; Reidman, J; Weizman, R, 2002) |
| "Weight gain induced by clozapine or olanzapine appears to be associated with an increase in leptin level that cannot be attributed to dietary changes upon hospitalization." | 3.70 | Body weight and leptin plasma levels during treatment with antipsychotic drugs. ( Haack, M; Hinze-Selch, D; Kraus, T; Kühn, M; Pollmächer, T; Schuld, A; Uhr, M, 1999) |
| "Weight gain was positively correlated with changes in insulin levels, insulin resistance index and triglyceride levels." | 2.74 | Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population. ( Amado, JA; Berja, A; Crespo-Facorro, B; Garcia-Unzueta, MT; Martinez-Garcia, O; Mata, I; Pelayo-Teran, JM; Perez-Iglesias, R; Vazquez-Barquero, JL, 2009) |
| "Weight gain has become one of the most common and concerning side effects of antipsychotic treatment." | 2.73 | Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment. ( Amado, JA; Berja, A; Carrasco-Marín, E; Crespo-Facorro, B; Garcia-Unzueta, MT; Mata, I; Pelayo-Terán, JM; Perez-Iglesias, R; Vazquez-Barquero, JL, 2008) |
| "Most traditional neuroleptics have a narrow therapeutic-to-toxic index, and thus, the novel antipsychotics are the result of a search to substantially widen the distance between the dose that treats psychosis and the one that produces adverse effects." | 2.40 | The relationship of pharmacology to side effects. ( Casey, DE, 1997) |
| "Polydipsia was the most prevalent (24, 60." | 1.51 | Adverse drug reactions experienced by out-patients taking chlorpromazine or haloperidol at Zomba Mental Hospital, Malawi. ( Chikowe, I; Domingo, M; Kampira, E; Mafuta, C; Mwakaswaya, V; Parveen, S, 2019) |
| "Treatment with Bifeprunox was found to significantly reduce all of the measured parameters except white fat mass compared to the control group." | 1.40 | Different effects of bifeprunox, aripiprazole, and haloperidol on body weight gain, food and water intake, and locomotor activity in rats. ( De Santis, M; Deng, C; Huang, XF; Lian, J; Pan, B, 2014) |
| "Haloperidol patients were more often single and institutionalised, less educated, had more residual schizophrenia, were longer hospitalised in the previous year, took more corrective and psychotropic drugs and had more extrapyramidal symptoms (EPS) and gynaecomastia (all significantly)." | 1.35 | Belgian Schizophrenia Outcome Survey - results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol. ( Albert, A; De Graeve, D; Gillain, B; Peuskens, J; Van Vleymen, B, 2009) |
| "Body weight gain is a worrying side effect of many new antipsychotic drugs." | 1.33 | Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration. ( de Beaurepaire, R; Even, PC; Goubern, M; Minet-Ringuet, J; Tomé, D, 2006) |
| "Weight gain is one side effect of many antipsychotic drugs (APDs)." | 1.31 | Differential activation of orexin neurons by antipsychotic drugs associated with weight gain. ( Bubser, M; Deutch, AY; Fadel, J, 2002) |
| "Both haloperidol and clozapine treatment reduced the weight gain of the rats." | 1.29 | Differential Fos-protein induction in rat forebrain regions after acute and long-term haloperidol and clozapine treatment. ( Koch, T; Korf, J; Sebens, JB; Ter Horst, GJ, 1995) |
| "Haloperidol (HPL) was administered by presenting HPL-admixed food to 20 male and 19 female Sprague-Dawley rats from the age of 5 weeks at a target dose of 1." | 1.29 | Toxicological study on rats fed haloperidol: 80 week chronic toxicity test. ( Itoh, T; Itsukaichi, O; Masuda, Y; Saito, H; Yoshida, H, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (14.46) | 18.2507 |
| 2000's | 50 (60.24) | 29.6817 |
| 2010's | 19 (22.89) | 24.3611 |
| 2020's | 2 (2.41) | 2.80 |
| Authors | Studies |
|---|---|
| Kroeze, WK | 1 |
| Hufeisen, SJ | 1 |
| Popadak, BA | 1 |
| Renock, SM | 1 |
| Steinberg, S | 1 |
| Ernsberger, P | 1 |
| Jayathilake, K | 1 |
| Meltzer, HY | 1 |
| Roth, BL | 1 |
| Kim, SF | 1 |
| Huang, AS | 1 |
| Snowman, AM | 1 |
| Teuscher, C | 1 |
| Snyder, SH | 1 |
| Lange, JH | 1 |
| Reinders, JH | 1 |
| Tolboom, JT | 1 |
| Glennon, JC | 1 |
| Coolen, HK | 1 |
| Kruse, CG | 1 |
| Chen, Y | 2 |
| Wang, S | 1 |
| Xu, X | 1 |
| Liu, X | 2 |
| Yu, M | 1 |
| Zhao, S | 1 |
| Liu, S | 1 |
| Qiu, Y | 1 |
| Zhang, T | 1 |
| Liu, BF | 2 |
| Zhang, G | 2 |
| Gao, L | 1 |
| Hao, C | 1 |
| Chen, J | 1 |
| Ma, R | 1 |
| Zheng, L | 1 |
| Wu, Q | 1 |
| Jin, J | 1 |
| Wu, H | 1 |
| Siafis, S | 1 |
| Hamza, T | 1 |
| Schneider-Thoma, J | 1 |
| Davis, JM | 1 |
| Salanti, G | 1 |
| Leucht, S | 2 |
| Barber, S | 1 |
| Olotu, U | 1 |
| Corsi, M | 1 |
| Cipriani, A | 1 |
| Harvey, PD | 2 |
| Nakamura, H | 1 |
| Murasaki, M | 1 |
| Chikowe, I | 1 |
| Domingo, M | 1 |
| Mwakaswaya, V | 1 |
| Parveen, S | 1 |
| Mafuta, C | 1 |
| Kampira, E | 1 |
| Pérez-Iglesias, R | 5 |
| Martínez-García, O | 4 |
| Pardo-Garcia, G | 1 |
| Amado, JA | 5 |
| Garcia-Unzueta, MT | 5 |
| Tabares-Seisdedos, R | 1 |
| Crespo-Facorro, B | 5 |
| McEvoy, JP | 4 |
| Byerly, M | 1 |
| Hamer, RM | 1 |
| Dominik, R | 1 |
| Swartz, MS | 1 |
| Rosenheck, RA | 1 |
| Ray, N | 1 |
| Lamberti, JS | 1 |
| Buckley, PF | 1 |
| Wilkins, TM | 1 |
| Stroup, TS | 2 |
| De Santis, M | 1 |
| Pan, B | 1 |
| Lian, J | 1 |
| Huang, XF | 2 |
| Deng, C | 2 |
| Tardy, M | 1 |
| Huhn, M | 1 |
| Kissling, W | 1 |
| Engel, RR | 1 |
| Robertson, SH | 1 |
| Boomhower, SR | 1 |
| Rasmussen, EB | 1 |
| Korade, Ž | 1 |
| Liu, W | 1 |
| Warren, EB | 1 |
| Armstrong, K | 1 |
| Porter, NA | 1 |
| Konradi, C | 1 |
| Mata, I | 2 |
| Pelayo-Teran, JM | 3 |
| Berja, A | 2 |
| Vazquez-Barquero, JL | 4 |
| Meena, H | 1 |
| Nakhate, KT | 1 |
| Kokare, DM | 1 |
| Subhedar, NK | 1 |
| Peuskens, J | 1 |
| Gillain, B | 1 |
| De Graeve, D | 1 |
| Van Vleymen, B | 1 |
| Albert, A | 1 |
| Krakowski, M | 1 |
| Czobor, P | 2 |
| Citrome, L | 3 |
| Victoriano, M | 1 |
| Hermier, D | 1 |
| Even, PC | 4 |
| Fromentin, G | 1 |
| Huneau, JF | 1 |
| Tomé, D | 4 |
| de Beaurepaire, R | 4 |
| Kirk, SL | 1 |
| Glazebrook, J | 1 |
| Grayson, B | 1 |
| Neill, JC | 2 |
| Reynolds, GP | 1 |
| Correll, CU | 1 |
| Sheridan, EM | 1 |
| DelBello, MP | 1 |
| von Wilmsdorff, M | 2 |
| Bouvier, ML | 2 |
| Henning, U | 2 |
| Schmitt, A | 2 |
| Gaebel, W | 2 |
| Stauffer, VL | 1 |
| Case, M | 1 |
| Kinon, BJ | 6 |
| Conley, R | 1 |
| Ascher-Svanum, H | 3 |
| Kollack-Walker, S | 1 |
| Kane, J | 1 |
| McEvoy, J | 1 |
| Lieberman, J | 1 |
| Sertié, AL | 1 |
| Suzuki, AM | 1 |
| Sertié, RA | 1 |
| Andreotti, S | 1 |
| Lima, FB | 1 |
| Passos-Bueno, MR | 1 |
| Gattaz, WF | 2 |
| Klemp, M | 1 |
| Tvete, IF | 1 |
| Skomedal, T | 1 |
| Gaasemyr, J | 1 |
| Natvig, B | 1 |
| Aursnes, I | 1 |
| Covell, NH | 1 |
| Schooler, NR | 1 |
| Jackson, CT | 1 |
| Rojas, IA | 1 |
| Essock, SM | 1 |
| Detke, HC | 1 |
| Zhao, F | 1 |
| Witte, MM | 1 |
| Schneider-Axmann, T | 1 |
| Fadel, J | 1 |
| Bubser, M | 1 |
| Deutch, AY | 1 |
| Hermida, T | 1 |
| Franco, K | 1 |
| Hadi, F | 1 |
| Douyon, K | 1 |
| Baymiller, SP | 1 |
| Ball, P | 1 |
| McMahon, RP | 1 |
| Buchanan, RW | 2 |
| Wirshing, DA | 2 |
| Boyd, JA | 1 |
| Meng, LR | 1 |
| Ballon, JS | 1 |
| Marder, SR | 2 |
| Wirshing, WC | 2 |
| Atmaca, M | 1 |
| Kuloglu, M | 1 |
| Tezcan, E | 1 |
| Gecici, O | 1 |
| Ustundag, B | 1 |
| Lindenmayer, JP | 1 |
| Volavka, J | 1 |
| Sheitman, B | 1 |
| Cooper, TB | 1 |
| Chakos, M | 1 |
| Lieberman, JA | 2 |
| Gupta, S | 1 |
| Pouzet, B | 1 |
| Mow, T | 1 |
| Kreilgaard, M | 1 |
| Velschow, S | 1 |
| Bobes, J | 2 |
| Rejas, J | 2 |
| Garcia-Garcia, M | 1 |
| Rico-Villademoros, F | 1 |
| García-Portilla, MP | 1 |
| Fernández, I | 1 |
| Hernández, G | 1 |
| Collier, DA | 1 |
| Mosolov, SN | 1 |
| Kabanov, SO | 1 |
| Dossenbach, M | 1 |
| Erol, A | 1 |
| el Mahfoud Kessaci, M | 1 |
| Shaheen, MO | 1 |
| Sunbol, MM | 1 |
| Boland, J | 1 |
| Hodge, A | 1 |
| O'Halloran, RA | 1 |
| Bitter, I | 1 |
| Fell, MJ | 1 |
| Marshall, KM | 1 |
| Sahli, Ch | 1 |
| Bryois, Ch | 1 |
| Cañas, F | 1 |
| Mackell, J | 1 |
| Stensland, M | 1 |
| Zhao, Z | 1 |
| Schooler, N | 1 |
| Rabinowitz, J | 1 |
| Davidson, M | 1 |
| Emsley, R | 1 |
| Kopala, L | 1 |
| McGorry, PD | 1 |
| Van Hove, I | 1 |
| Eerdekens, M | 1 |
| Swyzen, W | 1 |
| De Smedt, G | 1 |
| Koga, M | 1 |
| Nakayama, K | 1 |
| Stensland, MD | 1 |
| Tollefson, GD | 5 |
| Zipursky, RB | 1 |
| Gu, H | 1 |
| Green, AI | 1 |
| Perkins, DO | 1 |
| Tohen, MF | 1 |
| Strakowski, SM | 1 |
| Sharma, T | 1 |
| Kahn, RS | 1 |
| Gur, RE | 1 |
| Minet-Ringuet, J | 3 |
| Goubern, M | 1 |
| Lacroix, M | 1 |
| Lin, EJ | 1 |
| Lee, NJ | 1 |
| Slack, K | 1 |
| Karl, T | 1 |
| Duffy, L | 1 |
| O'brien, E | 1 |
| Matsumoto, I | 1 |
| Dedova, I | 1 |
| Herzog, H | 1 |
| Sainsbury, A | 1 |
| Valet, P | 1 |
| Carpéné, C | 1 |
| Visentin, V | 1 |
| Prévot, D | 1 |
| Daviaud, D | 1 |
| Quignard-Boulange, A | 1 |
| Tamayo, JM | 1 |
| Mazzotti, G | 1 |
| Tohen, M | 1 |
| Zapata, R | 1 |
| Castillo, JJ | 1 |
| Fahrer, RD | 1 |
| González-Pinto, AM | 1 |
| Vieta, E | 1 |
| Azorin, JM | 1 |
| Brown, E | 1 |
| Brunner, E | 1 |
| Rovner, J | 1 |
| Bonett-Perrin, E | 1 |
| Baker, RW | 1 |
| Strassnig, M | 1 |
| Miewald, J | 1 |
| Keshavan, M | 1 |
| Ganguli, R | 1 |
| Archer, T | 1 |
| Fredriksson, A | 1 |
| Kumra, S | 1 |
| Oberstar, JV | 1 |
| Sikich, L | 1 |
| Findling, RL | 1 |
| McClellan, JM | 1 |
| Vinogradov, S | 1 |
| Charles Schulz, S | 1 |
| Gencer, O | 1 |
| Emiroglu, FN | 1 |
| Miral, S | 1 |
| Baykara, B | 1 |
| Baykara, A | 1 |
| Dirik, E | 1 |
| Ramirez-Bonilla, ML | 2 |
| Gonzalez-Blanch, C | 1 |
| Alvarez-Jimenez, M | 1 |
| Saddichha, S | 1 |
| Ameen, S | 1 |
| Akhtar, S | 1 |
| Han, M | 1 |
| Burne, TH | 1 |
| Newell, KA | 1 |
| Carrasco-Marín, E | 1 |
| Yoshida, H | 1 |
| Itsukaichi, O | 1 |
| Saito, H | 1 |
| Masuda, Y | 1 |
| Itoh, T | 1 |
| Sebens, JB | 1 |
| Koch, T | 1 |
| Ter Horst, GJ | 1 |
| Korf, J | 1 |
| Lawson, WB | 1 |
| Karson, CN | 1 |
| Bustillo, JR | 1 |
| Irish, D | 1 |
| Breier, A | 1 |
| Hummer, M | 1 |
| Kemmler, G | 1 |
| Kurz, M | 1 |
| Kurzthaler, I | 1 |
| Oberbauer, H | 1 |
| Fleischhacker, WW | 1 |
| Beasley, CM | 1 |
| Tran, PV | 1 |
| Casey, DE | 1 |
| Kraus, T | 1 |
| Haack, M | 1 |
| Schuld, A | 1 |
| Hinze-Selch, D | 1 |
| Kühn, M | 1 |
| Uhr, M | 1 |
| Pollmächer, T | 1 |
| Schmitt, U | 1 |
| Dahmen, N | 1 |
| Fischer, V | 1 |
| Weigmann, H | 1 |
| Rao, ML | 1 |
| Reuss, S | 1 |
| Hiemke, C | 1 |
| Kysar, L | 1 |
| Berisford, MA | 1 |
| Goldstein, D | 1 |
| Pashdag, J | 1 |
| Mintz, J | 1 |
| Stern, JM | 1 |
| Keer, SE | 1 |
| Rosenheck, R | 1 |
| Chang, S | 1 |
| Choe, Y | 1 |
| Cramer, J | 1 |
| Xu, W | 1 |
| Thomas, J | 1 |
| Henderson, W | 1 |
| Charney, D | 1 |
| Jones, B | 1 |
| Basson, BR | 3 |
| Walker, DJ | 1 |
| Crawford, AM | 1 |
| Gilmore, JA | 2 |
| Taylor, CC | 1 |
| Szymanski, KA | 1 |
| Ratzoni, G | 1 |
| Gothelf, D | 2 |
| Brand-Gothelf, A | 1 |
| Reidman, J | 1 |
| Kikinzon, L | 1 |
| Gal, G | 1 |
| Phillip, M | 2 |
| Apter, A | 2 |
| Weizman, R | 1 |
| Falk, B | 1 |
| Singer, P | 1 |
| Kairi, M | 1 |
| Zigel, L | 1 |
| Poraz, I | 1 |
| Frishman, S | 1 |
| Constantini, N | 1 |
| Zalsman, G | 1 |
| Weizman, A | 1 |
| Tu, JB | 1 |
| Hartridge, C | 1 |
| Izawa, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Orally-Disintegrating vs. Regular Olanzapine Tablets: Effects on Weight and GI Hormones[NCT00384332] | Phase 4 | 20 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| A Comparison of Long-Acting Injectable Medications for Schizophrenia[NCT01136772] | Phase 4 | 311 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| Comparative Efficacy and Acceptability of Lithium, Valproate, Oxcarbazepine, Quetiapine, Olanzapine, and Ziprasidone in Bipolar I Disorder, Manic or Mixed Phase[NCT01893229] | Phase 4 | 120 participants (Anticipated) | Interventional | 2013-09-30 | Recruiting | ||
| Effectiveness of Switching Antipsychotic Medications[NCT00044655] | Phase 4 | 219 participants (Actual) | Interventional | 2001-07-31 | Completed | ||
| A Double-Blind, Randomized Study Comparing Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia[NCT00088478] | Phase 3 | 402 participants (Actual) | Interventional | 2004-06-30 | Completed | ||
| Transcranial Magnetic Stimulation for Individuals With Tourette's Syndrome[NCT00529308] | Phase 2 | 20 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Aripiprazole for Clozapine Associated Medical Morbidity[NCT00345033] | Phase 4 | 38 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| Outcome Evaluation of Solutions for Wellness and Team Solutions Program in Patients With Severe Mental Illness[NCT00661869] | 295 participants (Actual) | Interventional | 2006-09-30 | Completed | |||
| A Placebo-Controlled, Cross-Over Trial of Aripiprazole Added to Obese Olanzapine-Treated Patients With Schizophrenia[NCT00351936] | Phase 4 | 16 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| Reduction of Body Weight in Olanzapine Treated Schizophrenia Patients by Adjunctive Supplementation of Antioxidants (Vitamins E + C) Plus Omega-3 Fatty Acids[NCT00211562] | Phase 3 | 20 participants (Actual) | Interventional | 2005-10-31 | Terminated | ||
| Effects of Atypical Antipsychotics on Appetite and Eating Behavior of Schizophrenia Patients: Analysis for Three Drugs, Olanzapine, Risperidone, and Aripiprazole, Known to Induce Different Degrees of Weight Gain[NCT01043250] | 81 participants (Actual) | Observational | 2009-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Montgomery Asberg Depression Rating Scale (MADRS) total score. Construct: Depression severity. Scores below represent mean change scores, endpoint minus baseline. Minimum total score: 0 (no depression). Maximum total score: 60 (severe depression). Lower (more negative) scores indicate a better outcome. There are no subscales. (NCT00384332)
Timeframe: 10 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Arm 1 | -15.5 |
| Arm 2 | -15.5 |
Change in weight from baseline to endpoint in kilograms. Reported as weight in Kilograms at Baseline, Weeks 1, 4, 6, and 8 (NCT00384332)
Timeframe: 10 weeks
| Intervention | kilograms (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Week 1 | Week 4 | Week 6 | Week 8 | |
| Arm 1- ODT | 76.0 | 77.4 | 77.8 | 78.9 | 79.1 |
| Arm 2- SOT | 76.1 | 77.6 | 78.3 | 79.4 | 80.1 |
The Positive and Negative Syndrome Scale measures the core symptoms associated with schizophrenia. The measure includes 30 items rated from 1=absent to 7=extremely severe. Full range of scores is 30-210 with higher scores representing more severe illness. Reductions in symptoms over time represent improvement. (NCT01136772)
Timeframe: Baseline to 6 months
| Intervention | Units on a scale (Mean) |
|---|---|
| Paliperidone Palmitate | -6.87 |
| Haloperidol Decanoate | -6.40 |
Efficacy failure as indicated by psychiatric hospitalization, need for crisis intervention, clinical decision that oral antipsychotic medication cannot be discontinued in less than eight weeks, a clinical decision to discontinue the medication due to inadequate benefit, or the ongoing or repeated need for adjunctive antipsychotic medication. (NCT01136772)
Timeframe: 24 months
| Intervention | participants (Number) |
|---|---|
| Paliperidone Palmitate | 49 |
| Haloperidol Decanoate | 47 |
(NCT00044655)
Timeframe: Measured at Six Months
| Intervention | participants (Number) |
|---|---|
| Stay | 11 |
| Switch | 23 |
"The CGI-I is a clinician-rated scales that have been used in clinical trials for over 25 years. Clinicians rate patient improvement compared to baseline. By convention, 4 = No Change; scores of 5, 6, and 7 move in the direction of worsening; scores of 3, 2, and 1 correspond to Minimal Improvement, Much Improved or Very Much Improved, respectively. CGI-I ratings of Much or Very Much Improved at post-treatment are used to identify treatment responders." (NCT00529308)
Timeframe: 3 weeks
| Intervention | participants (Number) |
|---|---|
| Active | 2 |
| Sham | 8 |
"The CGI-I is a clinician-rated scales that have been used in clinical trials for over 25 years. Clinicians rate patient improvement compared to baseline. By convention, 4 = No Change; scores of 5, 6, and 7 move in the direction of worsening; scores of 3, 2, and 1 correspond to Minimal Improvement, Much Improved or Very Much Improved, respectively. CGI-I ratings of Much or Very Much Improved at post-treatment are used to identify treatment responders." (NCT00529308)
Timeframe: 3 weeks
| Intervention | participants (Number) |
|---|---|
| Active | 1 |
| Sham | 0 |
Motor Threshold (MT) is thought to be a measure of membrane excitability in pyramidal neurons. MT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 µV in peak to peak amplitude) in a resting target muscle in 5 out of 10 trials using single pulse TMS administered to the contralateral primary motor cortex. MT for both right and left hand are determined, and the lowest is used to select the intensity for rTMS. (NCT00529308)
Timeframe: 3 weeks
| Intervention | µV (Mean) |
|---|---|
| Active | 56.5 |
| Sham | 63.8 |
Motor Threshold (MT) is thought to be a measure of membrane excitability in pyramidal neurons. MT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 µV in peak to peak amplitude) in a resting target muscle in 5 out of 10 trials using single pulse TMS administered to the contralateral primary motor cortex. MT for both right and left hand are determined, and the lowest is used to select the intensity for rTMS. (NCT00529308)
Timeframe: 3 weeks
| Intervention | µV (Mean) |
|---|---|
| Active | 56 |
| Sham | 59.8 |
Y-GTSS is a clinician-rated scale used to assess tic severity. Motor and phonic tics are rated separately from 0 to 5 on several scales including number, frequency, intensity, complexity, and interference. Thus Motor and Phonic Tic scores can range from 0 to 25; the combined Total Tic Score ranges from 0 to 50. There is also an Impairment score that rates the overall burden due to tics. The Impairment scale yields a single score from 0 to 50 with higher scores indicating higher levels of overall impairment associated with tics. (NCT00529308)
Timeframe: 3 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Active | 29.5 |
| Sham | 31.5 |
A comparison between aripiprazole group and placebo group of change in Body Mass Index (BMI) measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | kg/m^2 (Mean) |
|---|---|
| Aripiprazole | -0.52 |
| Placebo | 0.03 |
A comparison between the aripiprazole group and placebo group in change in glucose metabolism measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | min^-1 (Mean) |
|---|---|
| Aripiprazole | 0.003 |
| Placebo | -0.005 |
A comparison between aripiprazole group and placebo group of change in insulin resistance measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | HOMA score (Mean) |
|---|---|
| Aripiprazole | 0.6 |
| Placebo | 0.65 |
A comparison of aripiprazole group and placebo group in change in total cholesterol measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -15.3 |
| Placebo | 5.6 |
(NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -5.9 |
| Placebo | -7.3 |
A comparison between aripiprazole group and placebo group in change in weight measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | kg (Mean) |
|---|---|
| Aripiprazole | -1.5 |
| Placebo | 0.3 |
Evaluating change in Body Mass Index (BMI) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | kg/m^2 (Mean) |
|---|---|
| Aripiprazole | -0.4 |
| Placebo | 0.3 |
Evaluating change in fasting total cholesterol between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -3 |
| Placebo | 9 |
Evaluating change in high-density lipoprotein cholesterol (HDL-C) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | 0.4 |
| Placebo | 0.6 |
Evaluating change in low-density lipoprotein (LDL) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -0.2 |
| Placebo | 3.1 |
Evaluating change in triglyceride levels between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -51.7 |
| Placebo | 47.6 |
Evaluating change in waist-hip ratio (WHR) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | cm (Mean) |
|---|---|
| Aripiprazole | 0.0 |
| Placebo | 0.0 |
Evaluating change in weight (lbs) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | lbs (Mean) |
|---|---|
| Aripiprazole | -2.9 |
| Placebo | 2.1 |
13 reviews available for haloperidol and Weight Gain
| Article | Year |
|---|---|
Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized Controlled Trials.
Topics: Adult; Antipsychotic Agents; Haloperidol; Humans; Olanzapine; Randomized Controlled Trials as Topic; | 2022 |
Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Clozapine; Dibenzothiazepines; Drug Resistan | 2017 |
Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia.
Topics: Antipsychotic Agents; Dyskinesia, Drug-Induced; Haloperidol; Humans; Patient Dropouts; Randomized Co | 2014 |
Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials.
Topics: Adolescent; Adult; Age Factors; Akathisia, Drug-Induced; Anti-Obesity Agents; Antimanic Agents; Anti | 2010 |
A review and Bayesian meta-analysis of clinical efficacy and adverse effects of 4 atypical neuroleptic drugs compared with haloperidol and placebo.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Bayes Theorem; Haloperidol; Humans; Randomized Control | 2011 |
Safety in treating bipolar disorder.
Topics: Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clozapine; Diabetes Melli | 2003 |
Pharmacogenetics in psychosis.
Topics: Antipsychotic Agents; Clozapine; Cytochrome P-450 Enzyme System; Drug Resistance; Dyskinesia, Drug-I | 2003 |
[The appearance of metabolic syndrome in treatment with atypical antipsychotics].
Topics: Adolescent; Adult; Age Factors; Aged; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body W | 2003 |
[Psychotropics and weight gain].
Topics: Adolescent; Adult; Amisulpride; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Aripi | 2004 |
Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Disorders of Excessive Som | 2008 |
Safety of olanzapine.
Topics: Acute Disease; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Blood Pressure; Clini | 1997 |
The relationship of pharmacology to side effects.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; D | 1997 |
Weight change and atypical antipsychotic treatment in patients with schizophrenia.
Topics: Antipsychotic Agents; Behavior Therapy; Benzodiazepines; Dose-Response Relationship, Drug; Follow-Up | 2001 |
28 trials available for haloperidol and Weight Gain
| Article | Year |
|---|---|
Blonanserin versus haloperidol in Japanese patients with schizophrenia: A phase 3, 8-week, double-blind, multicenter, randomized controlled study.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Tolerance; Female; Haloperidol; Humans; Male; | 2019 |
Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Male; Metabolic Disea | 2014 |
Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Double-Blind Method; Female; Haloperidol; Hosp | 2014 |
Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Cholesterol; Cholesterol, H | 2009 |
Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol.
Topics: Adult; Aggression; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body | 2009 |
Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Double-Blind Metho | 2011 |
Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial.
Topics: Antipsychotic Agents; Connecticut; Delayed-Action Preparations; Drug Substitution; Female; Fluphenaz | 2012 |
Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Hal | 2012 |
Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Cholesterol; D | 2012 |
Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic antagonist treatment.
Topics: Adrenergic beta-Antagonists; Adult; Analysis of Variance; Antipsychotic Agents; Atenolol; Blood Gluc | 2003 |
Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Cholesterol; Clozapine; Double-Bl | 2003 |
Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain.
Topics: Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Dyskinesia, Drug-Induced; Follow-Up St | 2004 |
Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Haloperido | 2005 |
Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Ind | 2005 |
Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Cholesterol; Double-Blind Method; Fem | 2005 |
Outcomes for Latin American versus White patients suffering from acute mania in a randomized, double-blind trial comparing olanzapine and haloperidol.
Topics: Acute Disease; Aged; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Cholesterol; Diagnosti | 2007 |
Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder. An open label maintenance study.
Topics: Adolescent; Adolescent Behavior; Antipsychotic Agents; Autistic Disorder; Child; Child Behavior; Dos | 2008 |
A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.
Topics: Adolescent; Adult; Anthropometry; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass In | 2007 |
Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naïve population.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Chronic Disease; Cohort S | 2008 |
Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Double-Blind Method; Female; Haloperi | 2008 |
Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment.
Topics: Adiponectin; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Body Composition; Body Mass I | 2008 |
Differential effect of clozapine on weight: a controlled study.
Topics: Ambulatory Care; Clozapine; Double-Blind Method; Follow-Up Studies; Haloperidol; Humans; Psychiatric | 1996 |
Weight gain induced by clozapine.
Topics: Adult; Antipsychotic Agents; Clozapine; Female; Haloperidol; Humans; Male; Schizophrenia; Weight Gai | 1995 |
Novel antipsychotics: comparison of weight gain liabilities.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Haloperidol; Humans; I | 1999 |
Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol.
Topics: Adult; Antipsychotic Agents; Black or African American; Clozapine; Double-Blind Method; Drug Adminis | 2000 |
Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Blood Pressure; Body Mass Index; Body W | 2001 |
Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.
Topics: Adult; Age Factors; Antipsychotic Agents; Appetite; Benzodiazepines; Body Mass Index; Body Weight; B | 2001 |
Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Eating; Energy Inta | 2002 |
42 other studies available for haloperidol and Weight Gain
| Article | Year |
|---|---|
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Discriminant Analysis; Drug Evaluation, Preclinical; Forecasting; Hum | 2003 |
From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase.
Topics: Adenylate Kinase; Animals; Antipsychotic Agents; Enzyme Activation; Hypothalamus; Immunohistochemist | 2007 |
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzoxazines; Biogenic Monoamines; Humans; Hyperprolac | 2007 |
Synthesis and biological investigation of coumarin piperazine (piperidine) derivatives as potential multireceptor atypical antipsychotics.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Biological Availability; Coumarins; ERG1 Potassiu | 2013 |
Discovery of a new class of multi-target heterocycle piperidine derivatives as potential antipsychotics with pro-cognitive effect.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Cognition; Dopamine; Drug Design; Humans; Hyperprol | 2021 |
Adverse drug reactions experienced by out-patients taking chlorpromazine or haloperidol at Zomba Mental Hospital, Malawi.
Topics: Adolescent; Adult; Antipsychotic Agents; Chlorpromazine; Cross-Sectional Studies; Erectile Dysfuncti | 2019 |
Different effects of bifeprunox, aripiprazole, and haloperidol on body weight gain, food and water intake, and locomotor activity in rats.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzoxazoles; Drinking Behavior; Feeding Behavior; Halo | 2014 |
High-fat diet alters weight, caloric intake, and haloperidol sensitivity in the context of effort-based responding.
Topics: Animals; Body Weight; Diet, High-Fat; Dietary Fats; Dopamine; Energy Intake; Feeding Behavior; Halop | 2017 |
Effect of psychotropic drug treatment on sterol metabolism.
Topics: Adult; Animals; Antidepressive Agents; Antipsychotic Agents; Body Mass Index; Cholestadienols; Cloza | 2017 |
GABAA receptors in nucleus accumbens shell mediate the hyperphagia and weight gain following haloperidol treatment in rats.
Topics: Animals; Antipsychotic Agents; Dose-Response Relationship, Drug; GABA Agonists; GABA Antagonists; GA | 2009 |
Belgian Schizophrenia Outcome Survey - results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Belgium; Benzodiazepines; Brief Psychiatric Rat | 2009 |
Early perturbation in feeding behaviour and energy homeostasy in olanzapine-treated rats.
Topics: Adiposity; Animals; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Eating; Energy Metabolism; | 2009 |
Olanzapine-induced weight gain in the rat: role of 5-HT2C and histamine H1 receptors.
Topics: Analysis of Variance; Animals; Behavior, Animal; Benzodiazepines; Dopamine Antagonists; Drug Interac | 2009 |
The impact of antipsychotic drugs on food intake and body weight and on leptin levels in blood and hypothalamic ob-r leptin receptor expression in wistar rats.
Topics: Animals; Antipsychotic Agents; Blotting, Western; Clozapine; Eating; Exploratory Behavior; Haloperid | 2010 |
Effects of antipsychotics with different weight gain liabilities on human in vitro models of adipose tissue differentiation and metabolism.
Topics: Adipocytes; Adipogenesis; Adipose Tissue; Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; F | 2011 |
The sex-dependent impact of chronic clozapine and haloperidol treatment on characteristics of the metabolic syndrome in a rat model.
Topics: Adiposity; Animals; Antipsychotic Agents; Blood Glucose; Body Weight; Clozapine; Drinking; Eating; F | 2013 |
Differential activation of orexin neurons by antipsychotic drugs associated with weight gain.
Topics: Amphetamine; Animals; Antipsychotic Agents; Body Weight; Carrier Proteins; Cell Count; Central Nervo | 2002 |
Weight gain associated with atypical antipsychotics.
Topics: Adolescent; Benzodiazepines; Child; Dopamine Antagonists; Female; Haloperidol; Humans; Male; Obesity | 2002 |
The effects of novel antipsychotics on glucose and lipid levels.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL | 2002 |
The effects of novel antipsychotics on glucose and lipid levels.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL | 2002 |
The effects of novel antipsychotics on glucose and lipid levels.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL | 2002 |
The effects of novel antipsychotics on glucose and lipid levels.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL | 2002 |
Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Diagnostic and Statistical Manual of Menta | 2003 |
Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Body Weight; Diet; Disease Models, Animal; Dose-Resp | 2003 |
Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Ambulatory Care; Antipsychotic Agents; Benzodiazepin | 2003 |
Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Diagnostic and Statistical Manual | 2004 |
Effects of the classical antipsychotic haloperidol and atypical antipsychotic risperidone on weight gain, the oestrous cycle and uterine weight in female rats.
Topics: Animals; Antipsychotic Agents; Dose-Response Relationship, Drug; Eating; Estrous Cycle; Female; Halo | 2004 |
[Expectations and developments in atypical antipsychotics].
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Clozapine; Diabetes Complicati | 2004 |
Body weight gain induced by a newer antipsychotic agent reversed as negative symptoms improved.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Diet; Exercise; Female; Haloperidol; H | 2005 |
Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Female; Haloperidol; H | 2005 |
Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration.
Topics: Adipose Tissue; Animal Feed; Animals; Antipsychotic Agents; Benzodiazepines; Eating; Haloperidol; Ma | 2006 |
A model for antipsychotic-induced obesity in the male rat.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Body Composition; Body Weight; Circadian Rhythm; Die | 2006 |
Distinct endocrine effects of chronic haloperidol or risperidone administration in male rats.
Topics: Adipose Tissue; Animals; Antipsychotic Agents; Appetite; Body Weight; Corticosterone; Diabetes Melli | 2006 |
Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment.
Topics: Adipocytes; Animals; Antipsychotic Agents; Benzodiazepines; Cell Size; Drug Administration Schedule; | 2007 |
Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis.
Topics: Adult; Affective Disorders, Psychotic; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Dose- | 2007 |
Functional consequences of iron overload in catecholaminergic interactions: the Youdim factor.
Topics: Animals; Animals, Newborn; Antipsychotic Agents; Brain Chemistry; Catecholamines; Clozapine; Denerva | 2007 |
Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression.
Topics: Adipose Tissue; Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Eating; Female; Halope | 2008 |
Toxicological study on rats fed haloperidol: 80 week chronic toxicity test.
Topics: Animals; Blepharitis; Drinking; Eating; Eyelids; Female; Haloperidol; Male; Motor Activity; Rats; Ra | 1995 |
Differential Fos-protein induction in rat forebrain regions after acute and long-term haloperidol and clozapine treatment.
Topics: Animals; Body Weight; Catalepsy; Clozapine; Haloperidol; Immunohistochemistry; Male; Prosencephalon; | 1995 |
Clinical correlates of body weight changes in schizophrenia.
Topics: Adult; Atrophy; Brain; Cerebral Ventricles; Energy Intake; Female; Haloperidol; Humans; Male; Psychi | 1994 |
Body weight and leptin plasma levels during treatment with antipsychotic drugs.
Topics: Adipose Tissue; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body W | 1999 |
Chronic oral haloperidol and clozapine in rats: A behavioral evaluation.
Topics: Administration, Oral; Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Clozapi | 1999 |
Maternal motivation of lactating rats is disrupted by low dosages of haloperidol.
Topics: Anesthesia; Animals; Denervation; Depression, Chemical; Dopamine Antagonists; Female; Haloperidol; L | 1999 |
Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Male; Mental Disorde | 2002 |
Psychopharmacogenetic aspects of Prader-Willi syndrome.
Topics: Adolescent; Aggression; Appetite Depressants; Behavior Therapy; Carbamazepine; Combined Modality The | 1992 |